Effect of Alpha Linolenic Acid Supplementation on Serum Prostate Specific Antigen PSA: Results from the Alpha Omega TrialReportar como inadecuado




Effect of Alpha Linolenic Acid Supplementation on Serum Prostate Specific Antigen PSA: Results from the Alpha Omega Trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

Alpha linolenic acid ALA is the major omega-3 fatty acid in the diet. Evidence on health effects of ALA is not conclusive, but some observational studies found an increased risk of prostate cancer with higher intake of ALA. We examined the effect of ALA supplementation on serum concentrations of prostate-specific antigen PSA, a biomarker for prostate cancer.

Methods

The Alpha Omega Trial ClinicalTrials.gov Identifier: NCT00127452 was a double-blind, placebo-controlled trial of ALA and the fish fatty acids eicosapentanoic acid EPA and docosahexanoic acid DHA on the recurrence of cardiovascular disease, using a 2×2 factorial design. Blood was collected at the start and the end of the intervention period. The present analysis included 1622 patients with a history of a myocardial infarction, aged 60–80 years with an initial PSA concentration <4 ng-mL. They received either 2 g per day of ALA or placebo in margarine spreads for 40 months. T-tests and logistic regression were used to assess the effects of ALA supplementation on changes in serum PSA both continuously and as a dichotomous outcome, cut-off point: >4 ng-mL.

Findings

Mean serum PSA increased by 0.42 ng-mL on placebo n = 815 and by 0.52 ng-mL on ALA n = 807, a difference of 0.10 95% confidence interval: −0.02 to 0.22 ng-mL P = 0·12. The odds ratio for PSA rising above 4 ng-mL on ALA versus placebo was 1.15 95% CI: 0.84–1.58.

Interpretation

An additional amount of 2 g of ALA per day increased PSA by 0.10 ng-mL, but the confidence interval ranged from −0.02 to 0.22 ng-mL and included no effect. Therefore, more studies are needed to establish whether or not ALA intake has a clinically significant effect on PSA or prostate cancer.

Trial registration information

ClinicalTrials.gov; Identifier: NCT00127452. URL: http:-www.clinicaltrials.gov-ct2-show-NCT00127452.



Autor: Ingeborg A. Brouwer , Johanna M. Geleijnse, Veronique M. Klaasen, Liesbeth A. Smit, Erik J. Giltay, Janette de Goede, Annemieke C

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados